{
  "id": 11450301,
  "title": "STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more",
  "url": "https://urgent.news/2026/10/02/stat-pharmalittle-were-reading-about-the-340b-drug-pilot-program-an",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T13:11:16.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/10/02/340b-drug-pilot-program-boehringer-zealand-obesity-trial/"
  },
  "original_language": "en",
  "account": "Boehringer Ingelheim and Zealand Pharma recently unveiled an obesity drug that only led to a 13.1% weight loss in diabetic patients, a disappointing outcome. Despite being marketed as a solution that maintains muscle mass, the drug faces stiff competition from existing treatments from Eli Lilly and Novo. Boehringer Ingelheim insists that upcoming studies on heart and liver health will reveal more about the drug's full potential.\n\nAs midterm elections approach, major changes may occur in key Senate committees overseeing healthcare policy. The Senate Finance Committee, which currently comprises 14 Republicans, will likely see significant turnover, with five or more leaving their positions. Meanwhile, the Senate Committee on Health, Education, Labor, and Pensions (HELP) faces an even greater uncertainty with the resignation of its chairman, Bill Cassidy.\n\nIn a separate development, Novartis has entered into a licensing agreement worth $7.8 billion with Chinese biotech firm Abogen. This deal grants Novartis exclusive rights to Abogen's experimental RNA-based therapy, ABO2203, along with options to license other treatments derived from Abogen's RNA technology. Additionally, Novartis holds the option to license any future therapies developed using Abogen's RNA platform, which targets B cells to treat autoimmune diseases such as lupus and rheumatoid arthritis.",
  "summary": "The U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providers",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}